Gilead's shares rose 1.3% to $62.30, while Merck was up nearly 2% at $76.08. It was also shown to stand up against variants first reported in the U.K., South Africa, Brazil, California, New York and India. Reporting By Mrinalika Roy in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles. Potential side effects include anaphylaxis and infusion-related reactions such as rash and diarrhea. Gilead and Merck will share global development and commercialization costs 60% and 40%, respectively, while having an equal share of the therapy's sales until the revenue crosses certain milestones.
Gilead's shares rose 3.33 percent to $60.32, while Merck was up dramatically 4% funds. It was also showed to stand up against different side effects.
( z0 multi-sentence :snt ( z1 contrast :ARG1 ( z2 rise :ARG1 ( z3 share :ARG0 ( z4 company :name ( z5 name :op "Gilead" ) ) ) :ARG2 ( z6 percentage-entity :value 3.33 ) :ARG4 ( z7 monetary-quantity :quant 60.32 :unit ( z8 dollar ) ) ) :ARG2 ( z9 up :ARG1 ( z10 company :name ( z11 name :op "Merck" ) ) :ARG2 ( z12 percentage-entity :ARG2-of ( z13 fund ) :value 4 ) :manner ( z14 dramatic ) ) ) :snt ( z15 show :ARG1 ( z16 stand-up :ARG0-of ( z17 oppose :ARG1 ( z18 effect :ARG1-of ( z19 differ ) :mod ( z20 side ) ) ) :ARG1 ( z21 it ) ) :mod ( z22 also ) ) )
(z0 / multi-sentence
    :snt1 (z1 / contrast-01
              :ARG1 (z2 / rise-01
                        :ARG1 (z3 / share-01
                                  :ARG0 (z4 / company
                                            :name (z5 / name
                                                      :op1 "Gilead")))
                        :ARG2 (z6 / percentage-entity
                                  :value 3.33)
                        :ARG4 (z7 / monetary-quantity
                                  :quant 60.32
                                  :unit (z8 / dollar)))
              :ARG2 (z9 / up-02
                        :ARG1 (z10 / company
                                   :name (z11 / name
                                              :op1 "Merck"))
                        :ARG2 (z12 / percentage-entity
                                   :ARG2-of (z13 / fund-01)
                                   :value 4)
                        :manner (z14 / dramatic)))
    :snt2 (z15 / show-01
               :ARG1 (z16 / stand-up-07
                          :ARG0-of (z17 / oppose-01
                                        :ARG1 (z18 / effect-03
                                                   :ARG1-of (z19 / differ-02)
                                                   :mod (z20 / side)))
                          :ARG1 (z21 / it))
               :mod (z22 / also)))
Gilead 's shares rose 3.33 percent to $ 60.32 , while Merck was up dramatically 4 % funds . It was also showed to stand up against different side effects .
z4 :name z5
z5 :op1 3
z3 :ARG0 z4
z2 :ARG1 z3
z6 :value 0
z2 :ARG2 z6
z2 :ARG4 z7
z7 :unit z8
z7 :quant 2
z1 :ARG1 z2
z10 :name z11
z11 :op1 4
z9 :ARG1 z10
z1 :ARG2 z9
z9 :manner z14
z12 :value 1
z9 :ARG2 z12
z12 :ARG2-of z13
z0 :snt1 z1
z15 :mod z22
z0 :snt2 z15
z15 :ARG1 z16
z16 :ARG1 z21
z16 :ARG0-of z17
z18 :mod z20
z18 :ARG1-of z19
z17 :ARG1 z18